Pharmaceutical Litigation

Clients turn to Sterne Kessler to handle their pharmaceutical IP litigation because we know what it takes to win across any venue—with the trial skills, technical depth, and patent knowledge that delivers results.

In the last five years, Sterne Kessler has acted as litigation counsel in more than 150 patent cases across 27 jurisdictions in federal district court. We are also one of the top five most active firms at the U.S. Court of Appeals for the Federal Circuit in that same time frame. Our award-winning team has a deep bench of experienced litigators representing biosimilars as well as generic and specialty brand pharmaceutical companies in high-profile patent litigation, including blockbuster Abbreviated New Drug Application (ANDA) and Biologics Price Competition and Innovation Act (BPCIA) matters.

The Sterne Kessler Advantage

Industry Focused Trial Teams

We are trial lawyers who know the science behind our clients’ products. Many of our team members hold Ph.D.s or advanced degrees in fields such as medicinal chemistry, biochemistry, pharmacology, immunology, and molecular and cell biology so we can quickly grasp the science and technologies at issue in a case. Our industry knowledge and insight are used to develop effective legal strategies and to explain complex technology and IP concepts to both judges and juries in a compelling way.

We understand the advancements in life sciences that are shaping the IP landscape and excel at handling the most complex, bet-the-company cases. Our litigation experience covers a wide variety of conditions, from dry eye and gastrointestinal disease to cancer and psychological disorders. We are also experienced with a broad list of products, ranging from topical emulsions to therapeutic antibodies. In addition, we manage cases involving related technology such as DNA sequencing and drug delivery devices.

Tailored Legal Strategies

Whether you are anticipating generic or biosimilar competition for key products, or contemplating a generic or biosimilar product launch, we understand the sophisticated IP issues that can arise in litigation. Our lawyers have particular depth of experience at the interface between patent law and the Food and Drug Administration’s (FDA) drug approval process. We excel at every phase of the ANDA or BPCIA process, helping innovators or companies contemplating generics or biosimilars to achieve their commercial objectives. Our team develops strong positions early in litigation, preparing a detailed case roadmap to identify essential discovery, and drive discovery to fill gaps in that roadmap. We have litigated cases involving formulations, methods of treatment, label carve-outs, and more.

Leaders Across Venues

We are particularly skilled at coordinating actions across multiple venues when a multi-venue strategy can be favorable for our clients, including in federal district and appellate courts and the International Trade Commission. We also collaborate with our Post-Grant Practice Group to challenge patents in inter partes review and post-grant proceedings before the Patent Trial and Appeal Board.

Working With Sterne Kessler

  • Your goals always come first. We know that our pharmaceutical clients’ strategic goals vary from case to case, and we tailor our approach to achieve those goals as efficiently as possible. From the outset, we align our strategy with your business objectives and focus on your ideal outcome. Whether you are seeking early settlement or planning to take a case through trial, our team has the proven experience to guide you through any type of IP dispute.
  • We help you expect the unexpected. Before the start of any matter, we work with you to define phases, assess risk, and identify important milestones. We can anticipate potential obstacles over the life of a case and develop a strategic plan to overcome them. By providing early and ongoing analysis of relevant patents, prior art, and products, we formulate strong positions on invalidity, non-infringement, and claim construction at the outset of litigation.
  • Communication is our highest priority. Litigation can be unpredictable, and we develop a communication plan with our clients to keep them well-informed through the life of a case. We regularly report on matters in an efficient and cost-effective way. We are also committed to developing budgets that align with your needs and expectations.

Awards & Rankings

  • Highly Recommended/Tier 1 for Hatch-Waxman Litigation, LMG Life Sciences (2017-2023)
  • Winner of “Hatch-Waxman Impact Case of the Year” award for Adapt Pharma v. Teva (Fed. Cir. 2022), LMG Life Sciences Americas Awards (2022)
  • Tier 1 for Biotechnology Law (National) and Patent Litigation (Regional, Washington, D.C.), U.S. News – Best Lawyers® Best Law Firms (2023)

Related Resources

Bylined Articles

Federal Circuit Cases Exploring a Year of Rules, Rulemaking, and Rule Enforcement at the PTAB

Sterne, Kessler, Goldstein & Fox February 8, 2024

Bylined Articles

The Changing Contours of IPR Estoppel Law

Sterne, Kessler, Goldstein & Fox February 8, 2024

Bylined Articles

Reexamination Statistics and the Federal Circuit’s SNQ Clarification/Expansion

Sterne, Kessler, Goldstein & Fox February 8, 2024

Bylined Articles

Key 2023 PTAB Statistics

Sterne, Kessler, Goldstein & Fox February 8, 2024

Bylined Articles

The Staying Power of Fintiv: The Effect of Parallel Litigation at the PTAB in 2023

Sterne, Kessler, Goldstein & Fox February 8, 2024

Bylined Articles

Watch Your Step – Discretionary Denial Under 325(d) Is Alive and Kicking

Sterne, Kessler, Goldstein & Fox February 8, 2024

Bylined Articles

2023 Changes in Director Review

Sterne, Kessler, Goldstein & Fox February 8, 2024

Bylined Articles

2023 PTAB Case Highlights

Sterne, Kessler, Goldstein & Fox February 8, 2024

Bylined Articles

2023 PTAB Year in Review: Editors’ Introduction

Sterne, Kessler, Goldstein & Fox February 8, 2024

Reports

2023 PTAB Year in Review: Analysis & Trends

Sterne, Kessler, Goldstein & Fox February 8, 2024

Press Release

Award-Winning PTAB Team Publishes 2023 PTAB Year in Review: Analysis & Trends Report

Sterne, Kessler, Goldstein & Fox February 8, 2024

In the News

Petition Watch: Patent Obviousness, ADA Trials, Spoofing

Law360 January 25, 2024

In the News

Teva Defeats Infringement Claims on Endocrine Drug

New Jersey Law Journal January 3, 2024

Firm Announcements

Sterne Kessler Secures Non-Infringement Win for Teva Pharmaceuticals

Sterne, Kessler, Goldstein & Fox January 3, 2024

Speaking Engagement

LSPN Chairman’s Opening Address and Closing Remarks

October 10, 2023 9:30 AM - 6:50 PM PST

Press Release

LMG Life Sciences Ranks Sterne Kessler and Seven Directors for Patent Litigation and Prosecution

Sterne, Kessler, Goldstein & Fox September 21, 2023

Podcast Recording & Transcript

Meat & Potatoes Episode 224: Paul A. Ainsworth, Sterne Kessler

September 13, 2023

Press Release

Sterne Kessler Presented With Two Top Honors at 2023 LMG Life Sciences Americas Awards

Sterne, Kessler, Goldstein & Fox September 8, 2023

Client Alert

Mind Your Ps and Qs, and Your PTAs Too

September 5, 2023

Speaking Engagement

FDA and PTO Panel

July 1, 2023 9:45 AM - 10:45 AM PST

Speaking Engagement

Preparing for Biosimilar Carve Outs: Will Skinny Labelling Work for Biosimilars?

June 27, 2023 4:15 PM - 5:15 PM PST

Speaking Engagement

2023 Focus on Pharma

April 14, 2023 8:30 AM - 6:00 PM PST

Bylined Articles

Introduction – Federal Circuit Appeals from the PTAB and ITC: Summaries of Key 2022 Decisions

Sterne, Kessler, Goldstein & Fox February 6, 2023

Bylined Articles

Watching the Pot™

Sterne, Kessler, Goldstein & Fox January 30, 2023

MarkIt to Market®

MarkIt to Market® – January 2023

January 30, 2023

In the News

Second Wave of Biosimilar Cases Sharpens Patent Counsel Focus

Managing IP January 27, 2023

In the News

The Three Developments Exciting US Patent Practitioners in 2023

Managing IP January 6, 2023

In the News

Patent Cases To Watch in 2023

Law360 January 2, 2023

In the News

Teva, Apotex Win Ax of Patents in Sleep Drug Suit

Law360 December 13, 2022

Speaking Engagement

Patents in the Cross-Hairs of the Affordable Drug Conversation

December 5, 2022 9:30 AM - 10:30 AM PST

Speaking Engagement

Opening Address and Closing Remarks

November 1, 2022 8:30 AM - 6:25 PM PST

In the News

Gilead Settles HIV Drugs Patent Suit on Eve of Bench Trial

Law360 September 12, 2022

Firm Announcements

Sterne Kessler Client Catalyst Pharmaceuticals, Inc. Reaches Patent Litigation Settlement

Sterne, Kessler, Goldstein & Fox July 14, 2022

In the News

New Trustees to Join Cornell Board

Cornell Chronicle June 2, 2022

Press Release

Super Lawyers Recognizes 14 Attorneys as 2022 “Super Lawyers” and “Rising Stars”

Sterne, Kessler, Goldstein & Fox May 1, 2022

In the News

ImmunoGen Patent Application Suit Sent Back to Court (1)

Bloomberg Law March 25, 2022

Speaking Engagement

Phoenix Issue VI

March 18, 2022 3:30 PM - 5:00 PM PST

In the News

Almirall Loses Appeal on Acne Treatment Patent at Fed. Cir.

Bloomberg Law March 14, 2022

In the News

Fed. Circ. Affirms PTAB’s Ax of Acne Drug Patent

Law360 March 14, 2022

Reports

2021 PTAB Year in Review: Analysis & Trends

Sterne, Kessler, Goldstein & Fox March 7, 2022

Bylined Articles

Biologics at the PTAB: Statistics and Insights into Notable Biologics Decisions

Sterne, Kessler, Goldstein & Fox March 7, 2022

Press Release

Sterne Kessler Publishes 2021 PTAB Year in Review: Analysis & Trends Report

Sterne, Kessler, Goldstein & Fox March 7, 2022

In the News

Litigator of the Week Runners-Up and Shout Outs

Law.com February 18, 2022

In the News

Federal Circuit Tosses Naloxone Patents

Law Street Media February 11, 2022

In the News

Teva Win Invalidating Narcan Patents Upheld by Federal Circuit

Bloomberg Law February 10, 2022

In the News

Split Fed. Circ. Won’t Restore 4 Narcan Patents

Law360 February 10, 2022

Reports

Federal Circuit Appeals from the PTAB and ITC: Summaries of Key 2021 Decisions

Sterne, Kessler, Goldstein & Fox February 3, 2022

Bylined Articles

Introduction – Federal Circuit Appeals from the PTAB and ITC: Summaries of Key 2021 Decisions

Sterne, Kessler, Goldstein & Fox February 3, 2022

Bylined Articles

Mylan Labs. Ltd v. Janssen Pharmaceutica, N.V., 989 F.3d 1375 (Fed. Cir. 2021)

Sterne, Kessler, Goldstein & Fox February 3, 2022

PTAB Strategies and Insights

PTAB Strategies and Insights – January 2022

January 31, 2022

Bylined Articles

Does the Limit Exist?: Negative Limitations in Novartis v. Accord

Sterne, Kessler, Goldstein & Fox January 31, 2022

Reports

PTAB Bar Association 2021 Appellate Year in Review

PTAB Bar Association January 14, 2022

In the News

Tribunal Rule Among Top Patent Litigation Issues Going Into 2022

Bloomberg Law December 28, 2021

MarkIt to Market®

MarkIt to Market® – December 2021

December 22, 2021

Bylined Articles

Watching the Pot™

Sterne, Kessler, Goldstein & Fox December 22, 2021

Press Release

Sterne Kessler and Seven Directors Earn Top-Tier Designations in 2021 LMG Life Sciences Rankings

Sterne, Kessler, Goldstein & Fox September 29, 2021

Press Release

Directors Ellison, Rozendaal, and Sterling Win Prominent LMG Life Sciences Americas Awards

Sterne, Kessler, Goldstein & Fox September 23, 2021

In the News

USPTO Faces Growing Pressure To Enter Battle Over Drug Pricing

Pink Sheet September 23, 2021

In the News

Adapt Faces Tough Questions in Bid to Revive Narcan Patents

Bloomberg Law August 2, 2021

In the News

IP Forecast: Fed. Circ. To Mull Narcan Patents

Law360 July 29, 2021

Bylined Articles

Open Questions Following Minerva v. Hologic

Westlaw Today July 8, 2021

PTAB Strategies and Insights

PTAB Strategies and Insights Newsletter – June 2021

June 30, 2021

In the News

SCOTUS Upholds ‘Century-Old’ Assignor Estoppel Doctrine

Intellectual Property Magazine June 30, 2021

In the News

Panel: Should Biologics Manufacturers Have to Disclose More About Their Patents?

The Center for Biosimilars April 20, 2021

MarkIt to Market®

MarkIt to Market® – March 2021

March 31, 2021

Speaking Engagement

Biologics Price Competition and Innovation Act: Current and Future Legal Challenges

March 30, 2021 2:20 PM - 3:20 PM PST

MarkIt to Market®

MarkIt to Market® – January 2021

January 28, 2021

Bylined Articles

Watching the Pot™

Sterne, Kessler, Goldstein & Fox P.L.L.C. January 28, 2021

In the News

Patent Litigation Trends To Watch In 2021

Law360 January 3, 2021

In the News

Justices Skip Case Horizon Said Puts 32K Patents At Risk

Law360 November 3, 2020

Press Release

Firm and Seven Directors Recognized in 2020 LMG Life Sciences Rankings

Sterne, Kessler, Goldstein & Fox P.L.L.C. October 6, 2020

Press Release

Sterne, Kessler, Goldstein & Fox Wins Two 2020 LMG Life Sciences Americas Awards

Sterne, Kessler, Goldstein & Fox P.L.L.C. September 24, 2020

Press Release

Directors Sterne, Goldstein, and Pelletier Among the 2021 “Best Lawyers in America”

Sterne, Kessler, Goldstein & Fox September 22, 2020

In the News

In Case You Missed It: Hottest Firms And Stories On Law360

Law360 September 11, 2020

Bylined Articles

Patent License Considerations After Fed. Circ. Enbrel Ruling

Law360 September 4, 2020

In the News

Patent Cases To Watch In The Second Half Of 2020

Law360 July 9, 2020

Client Alert

IP Hot Topic: Patent Prosecution Tool Kit

July 7, 2020

Reports

Patent Prosecution Tool Kit

Sterne, Kessler, Goldstein & Fox July 7, 2020

Bylined Articles

Implications of the BPCIA on the IP Strategies of Brand Companies and Biosimilar Developers

Sterne, Kessler, Goldstein & Fox July 7, 2020

In the News

Top 6 Patent Rulings Of 2020: A Midyear Report

Law360 June 29, 2020

Bylined Articles

Biopharma Patentees Must Navigate Inherent Obviousness

Law360 June 23, 2020

Press Release

Durkin, Ellison, and Talley Again Named Among “Top 250 Women in IP” by Managing IP

Sterne, Kessler, Goldstein & Fox P.L.L.C. June 11, 2020

In the News

Teva Invalidates Opiant Patents In Narcan Suit

Law360 June 5, 2020

Speaking Engagement

Pharma IPR Conference 2020

March 4, 2020 12:00 AM - 11:59 PM PST

Speaking Engagement

International IP Skills Summit (IIPSS)

February 26, 2020 12:00 AM - 11:59 PM PST

Bylined Articles

Fed. Circ. Amgen Biosimilar Ruling Raises IP Damages Risk

Law360 February 26, 2020

In the News

Federal Circuit Ruling Could Put Certain Drug Patents At Risk

Bloomberg Law December 31, 2019

Speaking Engagement

IP Forum for Life Sciences

December 8, 2019 1:00 PM - 11:30 AM PST

In the News

Teva Gets PTAB To Review Cushing’s Syndrome Drug Patent

Law360 November 21, 2019

In the News

PTAB Cuts Down Two More Allergan Restasis Patents

Law360 September 30, 2019

Bylined Articles

Proposed BPCIA reforms: More music, same dance

Managing Intellectual Property May 16, 2019

Speaking Engagement

13th Annual Paragraph IV Disputes

April 29, 2019

Bylined Articles

Biopharma Patent Applicants Should Consider a Rarely Used Strategy

Bloomberg Law March 18, 2019

In the News

Fed. Circ. Won’t Revisit Restasis Patent Ruling

Law360 March 6, 2019

Bylined Articles

Federal Circuit Issues Further Guidance On AIA Proceeding Standing To Appeal

Sterne, Kessler, Goldstein & Fox P.L.L.C February 22, 2019

Bylined Articles

What Cannabis Patent Applicants Can Learn From Biopharma

Law360 January 17, 2019

In the News

3 Takeaways From The PTAB’s Cannabis Experience

Law360 January 11, 2019

In the News

J&J Tells Fed. Circ. Judge Was Wrong To Nix Zytiga Patent

Law360 December 4, 2018

In the News

Fed. Circ. Rejects Bid For PTAB Tribal Immunity Rehearing

Law360 October 22, 2018

Press Release

IP Powerhouse Sterne, Kessler, Goldstein & Fox Celebrates 40th Anniversary

Sterne, Kessler, Goldstein & Fox October 2, 2018

In the News

No Need To Reconsider Immunity At PTAB, Fed. Circ. Hears

Law360 September 19, 2018

In the News

Generics Cos. Urge Fed. Circ. To Upend Depomed Patent Win

Law360 September 4, 2018

In the News

Fed. Circ. Impeding Biopharma Innovation, Justices Told

Law360 August 29, 2018

Bylined Articles

The impact of Oil States and SAS on the post-grant landscape

The Patent Lawyer July 31, 2018

In the News

5 Recent PTAB Decisions Attys Need To Know

Law360 June 6, 2018

In the News

Biologic Fights Drive PTAB Drug Challenges To Record High

Law360 February 8, 2018

Global Patent Prosecution

Global Patent Prosecution Newsletter – January 2018

January 10, 2018

Bylined Articles

Obviousness-Type Double Patenting Dangers in the U.S.

Sterne, Kessler, Goldstein & Fox January 10, 2018

Bylined Articles

Worldwide Divisional Strategy Considerations

Sterne, Kessler, Goldstein & Fox January 10, 2018

In the News

Patent Cases To Watch In 2018

Law360 January 1, 2018

Bylined Articles

A Post-Lexmark Plan for Multiple Inventive Methods of Use

Law360 November 22, 2017

In the News

Judge Hacks Away At Allergan’s Restasis Patents

Law360 October 18, 2017

Global Patent Prosecution

Global Patent Prosecution Newsletter – July 2017

July 17, 2017

Bylined Articles

Biosimilar Uptake and Patent Litigation in Japan

Sterne, Kessler, Goldstein & Fox July 17, 2017

Publication

Approved Biosimilar Products Around the World

Sterne, Kessler, Goldstein & Fox July 17, 2017

Bylined Articles

Top 5 PTAB Tips for Big Pharma

New Jersey Law Journal April 3, 2017

Bylined Articles

The Future of Forum-Shopping in a Post-TC Heartland World

IP Watchdog January 11, 2017

Bylined Articles

Pfizer v. Lee: Defective Restriction Requirement Stops Patent Term Adjustment

Maryland State Bar Association IP Law Update June 22, 2016

Bylined Articles

Patentees: Caveat Emptor of the ‘On-Sale Bar’!

Bloomberg BNA's Patent, Trademark & Copyright Journal May 6, 2016

Bylined Articles

The DAIMLER Series: Lessons In Personal Jurisdiction for Biologic and Biosimilar Litigants

Bloomberg BNA: Pharmaceutical Law & Industry Report May 6, 2016

Bylined Articles

Trade Secret Pitfalls For The Hatch-Waxman Litigant

Law360 April 14, 2016

Bylined Articles

Patent Term Extension Considerations For Regulated Products

Law360 March 18, 2016

Bylined Articles

The Impact of Reformulation Strategies on Pharmaceuticals, Biologics

BioProcess Online March 17, 2016

Bylined Articles

Navigating Foggy Water

MSBA Bar Bulletin March 9, 2016

Bylined Articles

ANDA Access Negotiations May Affect Attorney Fee Liability

Law360 February 25, 2016

Books and Chapters

ANDA Litigation: Strategies and Tactics for Pharmaceutical Patent Litigators

ABA Book Publishing January 31, 2016

Bylined Articles

Choosing Between Patent And Trade Secret Protection In A Biosimilar World

Biosimilar Development January 13, 2016

Bylined Articles

What to Know About Patent Reform Bills as We Head Into 2016

Law360 December 28, 2015

Bylined Articles

Diagnostic Method Patents — Not All Hope is Lost

Westlaw Journal: Intellectual Property December 8, 2015

In the News

ImmunoGen Cancer Patent Still Valid After Phigenix’s Dispute

Bloomberg BNA October 29, 2015

In the News

PTAB Upholds ImmunoGen’s Breast Cancer Drug Patent

Law360 October 28, 2015

Bylined Articles

The DAIMLER Series: Five Personal, Specific Lessons Learned for Hatch-Waxman ANDA Litigants

Bloomberg BNA Pharmaceutical Law & Industry Report September 11, 2015

Bylined Articles

The DAIMLER Series: District Courts Analyze Personal Jurisdiction in ANDA Cases

Bloomberg BNA: Pharmaceutical Law & Industry Report July 3, 2015

Bylined Articles

Some Declaratory Judgment Guidance for ANDA Litigants

Law360 April 9, 2015

Bylined Articles

The Daimler Confusion And Its Impact On ANDA Litigation

Law360 March 6, 2015

Bylined Articles

IPR: A 2nd Bite At The Apple For Hatch-Waxman Litigants

Law360 March 11, 2014